NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors


BELTSVILLE, Md., July 06, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1/2 clinical trial for NC762, a humanized B7-H4 monoclonal antibody.

Go here to see the original:
NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors

Related Posts